An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study

You may be eligible if

• Patients with hematologic malignancies completing a prior idelalisib study with a clinical benefit are eligible
• Women of childbearing potential must have a negative pregnancy test to be eligible
• Male patients, and female patients of childbearing potential, must agree to use method(s) of contraception specified in the protocol